TREATMENT OF SYNGAP1 ENCEPHALOPATHY
Application
US20260083758A1
Kind: A1
Mar 26, 2026
Assignee
Harmony Biosciences Management, Inc.
Inventors
Terri Sebree, John Messenheimer, Donna Gutterman
Abstract
The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
CPC Classifications
A61K 31/658
A61M 21/02
A61P 25/08
A61P 25/28
A61M 2021/0077
Filing Date
2025-11-28
Application No.
19403384